NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Yesterday | ||
NovaBridge Biosciences (NBP) (H1 2026) Earnings Call Highlights: Strong Cash Position and ... NovaBridge Biosciences (NBP) reports a debt-free balance sheet with $216 million in cash, advancing its lead asset givastomig toward a potential Phase 3 launch in Q4 2026. | ||
NovaBridge Biosciences Q2 2026 Earnings Call Summary Moby summary of NovaBridge Biosciences's Q2 2026 earnings call | ||
Older | ||
 Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth Just because a business does not make any money, does not mean that the stock will go down. For example, although... | ||
 Amazon downgraded, Roblox upgraded: Wall Street's top analyst calls Amazon downgraded, Roblox upgraded: Wall Street's top analyst calls | TThe Fly | |
Insider Spends US$5.1m Buying More Shares In NovaBridge Biosciences NovaBridge Biosciences ( NASDAQ:NBP ) shareholders (or potential shareholders) will be happy to see that the Executive... | ||
Is There An Opportunity With NovaBridge Biosciences' (NASDAQ:NBP) 40% Undervaluation? Key Insights The projected fair value for NovaBridge Biosciences is US$6.70 based on 2 Stage Free Cash Flow to Equity... | ||